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ABSTRACT
Background: Atopic dermatitis is a chronic or chronically relapsing, pruritic inflammatory skin disease. The in-
cidence of atopic dermatitis has dramatically increased during the past three decades in industrialized coun-
tries. We attempted to develop an improved method to induce an animal model of atopic dermatitis and to use it
to evaluate the efficacy of a Tec family kinase inhibitor.
Methods: We treated dermatitis-prone inbred mice, NCNga, by repetitive epicutaneous applications of a
house dust mite allergen and staphylococcal enterotoxin B to induce atopic dermatitis-like skin lesions.
Results: We established a highly efficient protocol to induce skin lesions in NCNga mice, which were his-
tologically and immunologically similar to human atopic dermatitis. Similar to human patients, serum IgE levels
were increased in dermatitis-induced mice. Consistent with the proposed roles of infiltrated immune cells in the
pathogenesis of human atopic dermatitis, skin lesions were treatable with terreic acid, an inhibitor of Tec family
kinases, as well as dexamethasone.
Conclusions: We established a highly efficient, highly reproducible protocol to induce skin lesions in NCNga
mice and successfully applied it to show the efficacy of terreic acid in treating skin lesions. This mouse model of
atopic dermatitis will be useful to study the pathogenetic processes of atopic dermatitis and to evaluate the effi-
cacy of drug candidates.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic or chronically re-
lapsing, pruritic inflammatory skin disease.1,2 The in-
cidence of AD has increased two- to threefold during
the past three decades in industrialized countries.
Systemic immunological abnormalities characteristic
of AD include sensitization with various allergens,
(e.g., foods, aeroallergens, microbes, and autoaller-
gens), high serum IgE levels, and skin lesions with
apoptotic keratinocytes and infiltration with immune
cells such as CD4+ T cells, eosinophils, and mast
cells. These T cells express IL-4, IL-5, and IL-13,3 and
numerous studies suggest an association between
AD development and type 2 helper T (Th2) cell-
skewed immune dysfunction. However, there are also
data suggesting that AD development is independent
of IgE, but correlates with an increase in interferon
(IFN)-γ-producing Th1 cells.4-6 AD patients often suf-
fer from skin infections and more than 90% of AD pa-
tients are colonized with Staphylococcus aureus. Acti-
vation of the immune cells7 and S. aureus infection8,9
are thought to be critical in the pathogenesis andor
worsening of skin lesions.
Several mouse models of human AD have been de-
veloped over the last decade, and have provided in-
sight into the pathogenesis of human AD.10-16 For ex-
ample, an ovalbumin epicutaneous sensitization
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model mimicked skin lesions of human AD with re-
gard to infiltration of CD3+ T cells, eosinophils, and
neutrophils and local expression of mRNAs for IL-4,
IL-5 and IFN-γ.11 Differential roles of IL-4, IL-5, and
IFN-γ in skin lesion development and leukocyte infil-
tration in this model were demonstrated using gene-
manipulated mice, whereas IgE was not required for
skin lesion development in this model.17
NCNga mice spontaneously develop AD-like skin
lesions under conventional (non-specific pathogen-
free) conditions.10 Skin lesions in NCNga mice were
characterized by infiltration of IL-4- and IL-5-
producing CD4+ T cells, mast cells and eosinophils,
as well as Th2 chemokines and their receptors, and
the elevation of serum IgE correlated with the onset
of skin lesion development.10,18 Under conventional
conditions these mice were infested with rodent
mites,19,20 and the eradication of the mites with iver-
mectin led to healing of skin lesions and reduced IgE
levels.19 However, the incidence of skin lesions in
these mice drastically varies from facility to facility
(<5% in our facility). Therefore, several groups used
mite extracts to induce dermatitis in NCNga
mice.21-25 Application of mite Dermatophagoides (a
common mite on humans) extracts on the skin
clearly induced dermatitis and elevated serum IgE, al-
though some studies showed low clinical scores of
the induced lesions. In this study, we attempted to in-
crease the efficiency of disease development and the
severity of disease by treating NCNga mice with
agents that are likely to be involved in the pathogene-
sis of AD, and established a highly efficient mouse
model to induce AD-like skin lesions with high clini-
cal scores. Using this model, we found that terreic
acid, an inhibitor of Tec family kinases that are cru-
cial to immune cell activation,26 is as efficacious as
dexamethasone in treating skin lesions.
METHODS
INDUCTION AND TREATMENT OF AD-LIKE SKIN
LESIONS
Mice were anesthetized and their backs were shaved.
Solutions of 500 ng of staphylococcal enterotoxin B
(SEB) (Sigma-Aldrich, St. Louis, MO, USA) and 10
μg of Dermatophagoides farinae extract (Der f) (100
μgml, Greer Laboratories, Lenoir, NC, USA) were
pipetted on a 1 cm × 1 cm square gauze pad placed
on the shaved area. This portion of the back skin was
occluded with a TegadermTM Transparent Dressing
(3M HealthCare, St. Paul, MN, USA) using bandages.
Three days later, the dressings were replaced with a
new one. Another 4 days later, the dressings were re-
moved and the mice were kept without treatment for
the next week. This 2-week cycle was repeated one or
two more times. The healthy skin mice used as a con-
trol throughout this project were treated with vehicle
alone. Clinical severity was scored by an investigator
who did not know the identities of mice 2 days after
removing the dressings in the last cycle. Clinical
scores were based on the severity (0, no symptoms;
1, mild; 2, intermediate; 3, severe) of four possible
symptoms (redness, bleeding, eruption, and scaling).
The mice with a clinical score of 9 or higher were
used for treatment with terreic acid (Kirin Brewery
Co., Tokyo, Japan), dexamethasone (Sigma-Aldrich),
or ampicillin (Sigma-Aldrich). Skin lesions were cov-
ered with a piece of gauze spotted with 100 μl of
these reagents or vehicle and occluded with Tegad-
ermTM. This treatment with fresh agents was re-
peated every other day (four times in total). Clinical
scoring and tissue sampling were done 2 days after
the last treatment. Animal experiments were ap-
proved by the Institutional Review Board and fol-
lowed the guidelines described in the “Guide for the
Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National
Research Council, and published by the National
Academy Press.
HISTOLOGICAL ANALYSIS
Dorsal skin samples were fixed in 10% formaldehyde,
paraffin embedded and cut into 6 μm sections. De-
paraffinized sections were stained with hematoxylin
and eosin (H&E), toluidine blue (pH 4.0) or Congo
red. The remaining part of the skin was embedded in
an OCT compound, snap frozen in liquid nitrogen
and stored at −80℃ until use. Frozen sections cut at 6
μm were incubated with rat antibodies to CD4 (1 :
100, Santa Cruz Biotechnology), CD8 (1 : 15, BD Bi-
osciences Pharmingen), or Mac-1 (1 : 12.5, BD Bi-
osciences Pharmingen). Secondary antibodies were
horseradish peroxidase-conjugated goat antibody to
rat IgG (1 : 50, BD Biosciences Pharmingen). Bound
antibodies were detected using the ImmunoCruzTM
Staining System (Santa Cruz Biotechnology) followed
by hematoxylin counterstaining. Cells were counted
under a microscope at a magnification of ×400 and ex-
pressed as the total number of the cells in five high-
power fields per section.
SERUM IMMUNOGLOBULINS
Serum IgE and IgG levels were measured using
enzyme-linked immunoassay kits purchased from BD
Biosciences Pharmingen (San Diego, CA, USA) and
Roche Applied Science (Indianapolis, IN, USA), re-
spectively.
REVERSETRANSCRIPTION-POLYMERASECHAIN
REACTION (RT-PCR) ANALYSIS OF CYTOKINE
GENE EXPRESSION
Skin lesions were sampled using a paper puncher.
RNA was extracted from axillary lymph nodes and
skin samples using a Trizol One Step RNA Reagent
(BioPioneer Inc., San Diego, CA, USA). cDNA syn-
thesis was prepared with SuperScript II reverse tran-
scriptase (Invitrogen, Carlsbad, CA, USA) using the
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Fig. 1 Der f/SEB-induced Skin Lesions. (A) The schedule for dermatitis induction is depicted. 
D/B, treatment with Der f and SEB. The periods when Der f/SEB-treated back skin is occluded 
with TegadermTM are also shown at the botom. (B) A representative mouse (Left) with skin le-
sions of a clinical score of 12 is shown along with a mouse (Right) with healthy skin. (C) Clinical 
scores after one and two rounds of Der f/SEB induction (Left). Each mouse is connected between 
their score after one round and that after two rounds of treatment to indicate that the scores are in-
creased after two rounds in a majority of mice. Cumulative clinical data on skin lesions induced by 
two or three rounds of Der f/SEB treatment are also shown (Right, n ＝ 153). Note that 76 of 153 
mice showed clinical scores of 9 or higher.
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isolated RNAs as templates and oligo (dT) as a
primer. PCR was performed on the cDNAs using ap-
propriate primers for amplification of IL-4, IL-13 and
IFN-γ. The PCR products were analyzed by agarose
gel electrophoresis and quantified using a ChemDoc
XRS system densitometer and Quantity One software
(Bio-Rad, Hercules, CA, USA).
RESULTS
After several trials and errors, we found that epicuta-
neous application with Der f (house dust mite aller-
gen) and SEB is particularly efficient at inducing skin
lesions (Fig. 1). Clinical scores increased from 3.7 ±
2.2 after one round of one-week treatment with Der f
and SEB and one-week resting to 7.97 ± 2.2 after two
rounds of the same treatment (Fig. 1C). It is notewor-
thy that approximately 50% of the mice that under-
went two or three rounds of Der fSEB treatment ex-
hibited clinical scores of 9 or higher. This allowed for
easy evaluation of the effect of a drug candidate in
treating dermatitis. Cumulative results (n = 153) dem-
onstrated that this is a very efficient method to induce
skin lesions (Fig. 1C).
Microscopic analysis indicated that skin lesions ex-
hibit mild spongiosis, epidermal hyperplasia, and
parakeratosis, as well as infiltration with leukocytes
(Fig. 2A). Immunohistochemical staining demon-
strated that the numbers of CD4+ T cells and Mac-1+
monocytesmacrophages, but not CD8+ T cells, are
increased in skin lesions (Figs. 2A, B). Cell type-
specific stainings and H&E staining showed that the
lesions contained increased numbers of mast cells,
eosinophils, and neutrophils as well (Figs. 2A, B).
This pattern of leukocyte infiltration is quite similar to
human AD lesions and spontaneously developed skin
lesions in NCNga mice. Also similar to human AD,
disease-borne mice had increased serum IgE levels
(average values ± sd: 55.1 ± 4.1 μgml for Der fSEB-
treated mice on day 21 vs. <0.5 μgml for skin lesion-
free mice). Consistent with the role for Th2 cells in
the development of human AD and mouse AD mod-
els,12,17 draining lymph nodes had increased levels of
IL-4 mRNA (Fig. 3). However, IL-13 mRNA levels in
skin and lymph nodes were comparable between skin
lesion-borne and -unborne mice. Like human AD and
other AD mouse models including spontaneously de-
veloped skin lesions in NCNga mice,13,14,17,27 IFN-γ
mRNA levels also showed a tendency toward an in-
crease (not statistically significant) in Der fSEB-
induced skin lesions (Fig. 3).
Application of the same Der fSEB-resting cycle to
other strains of mice, C57BL6, BALBc and 129
SvJ, showed that NCNga mice are the most suscep-
tible to this form of dermatitis induction and that 129
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Fig. 2 Histological Analysis of Skin Lesions in Der f/SEB-treated Mice. (A) Untreated healthy 
skin and Der f/SEB-induced skin lesions were stained with H&E, anti-CD4, anti-Mac-1, and toluid-
ine blue (to stain mast cels, MC). (B) Celular data of skin lesions before and after treatment with 
Der f/SEB are shown (Top), combined with cel counts in the skin after therapeutic treatments with 
vehicle, tereic acid (TA) or dexamethasone (Dex)(Botom). Samples were taken from the thera-
peutic experiments shown in Figure 4C. Eror bars represent standard deviation.
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Fig. 3 RT-PCR Analysis of Cytokine Gene Expression in Der f/SEB-induced Skin Lesions and Draining 
Lymph Nodes. Untreated healthy skin (H) and Der f/SEB-induced AD-like skin lesions (AD) were sampled 
and RNA isolated. RT-PCR analysis was performed to measure mRNAs for IL-4, IL-13 and IFN-γ. 18S 
RNA was used for normalization. Representative agarose gels (Left) and cumulative data from 6 mice 
(Right) are shown. Eror bars represent standard deviation. P values obtained by Student’ st test are 
shown. NS denotes statisticaly not significant.
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SvJ and BALBc are the least susceptible (average
scores ± sd: 2.625 ± 2.5 for C57BL6 [n = 8];
0.125 ± 0.35 for BALBc [n = 8]; 0.00 for 129SvJ [n =
8]).
Current therapeutics for AD includes treatment
with emollients, topical corticosteroids, tacrolimus, or
pimecrolimus.1,28 In light of side effects of the current
therapies and some recalcitrant cases, we were inter-
ested in developing an alternative therapeutic ap-
proach. Activation of infiltrating immune cells, such
as T cells, eosinophils, mast cells, and monocytes
macrophages, are assumed to play critical roles in the
pathogenesis. Protein-tyrosine kinases of the Tec
family such as Itk, Btk, and Tec are important in the
Inhibition of Dermatitis by Terreic Acid
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Fig. 4 Therapeutic Efects of Tereic Acid on Der f/SEB-induced Skin Lesions. 
(A) NC/Nga mice were induced to develop skin lesions by three rounds of Der 
f/SEB treatments (see Fig. 1A for the treatment schedule). Mice with clinical scores 
of ＞＿ 9 were treated with 0% (vehicle), 0.01%, or 0.05% tereic acid on days 42, 44, 
46, and 48. Skin lesions were scored on days 40, 42, 44, 46, 48, and 50. Eror bars 
represent standard deviation and asterisks indicate statisticaly significant (p ＜ 
0.05) diferences between tereic acid-treated and vehicle-treated mice. N ＝ 6 for 
each group. Representative data out of 5 independent experiments are shown. (B) 
A representative mouse with tereic acid-treated skin lesions (Right) is shown 
along with a mouse treated with a vehicle (Left). (C) Experiments were performed 
similar to those shown in A (n ＝ 6 each group). The clinical scores after treatment 
with the indicated concentrations of tereic acid and dexamethasone are shown. Er-
ror bars represent standard deviation. P values obtained by Student’ st test are 
shown. NS denotes statisticaly not significant. (D) Efects of ampicilin are shown. 
Experiments were performed similar to those shown in A (n ＝ 6 each group).
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activation of the immune cells.29 We previously iden-
tified terreic acid, a quinone epoxide that was origi-
nally isolated as an antibiotic, as an inhibitor of this
class of kinases.26 To evaluate the effect of terreic
acid on skin lesions, we first checked the change in
skin lesions for 15 days after the last Der fSEB treat-
ment. Clinical scores of the mice that had scores of 9
or higher at day 40 stayed at high levels (> 8.5) for
the next 8 days and started to decline at day 50 (14th
day after the last Der fSEB treatment) (vehicle-
treated mice in Fig. 4A). When terreic acid was re-
peatedly (four times before scoring) applied to skin
lesions, clinical scores were significantly improved
over vehicle-treated controls (Figs. 4A, B). The ex-
tent of clinical improvement with 0.05% terreic acid
was approximately the same as that with 0.1%
dexamethasone-treated mice (Fig. 4C). Unlike dex-
amethasone treatment that left the skin reddish, how-
ever, terreic acid treatment did not have such an ad-
verse effect. Microscopic analysis of vehicle-treated
lesions demonstrated that, compared to the skin le-
sions before the treatment, numbers of CD4+ T cells
and eosinophils returned to basal levels 14 days after
the last Der fSEB treatment and mast cell numbers
also decreased, whereas numbers of monocytes
macrophages and neutrophils dramatically increased
Kawakami Y et al.
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Fig. 5 Efects of Tereic Acid and Dexamethasone on IgG 
and IgE in Der f/SEB-treated Mice. Serum IgG (A) or IgE (B) 
levels were not reduced in mice treated with tereic acid or 
dexamethasone (see Fig. 4C).
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during the same period (Fig. 2B). By contrast, treat-
ment with terreic acid or dexamethasone reversed
the infiltration of Mac-1+ monocytesmacrophages
and neutrophils to baseline, although high mast cell
levels were sustained (Fig. 2B). Interestingly, serum
IgE levels as well as IgG levels in terreic acid- and
dexamethasone-treated mice were only slightly lower
than those before the treatment, but much higher
than those in mice before dermatitis induction (Fig.
5). The IgE results are consistent with the notion that
IgE is not skin-pathogenic in NCNga mice, which
was supported by a previous study showing that
Stat6−− NCNga mice develop skin lesions without
increased serum IgE.30 The histopathological results
indicate that infiltrates of skin lesions in our AD model
become monocytemacrophage- and neutrophil-
dominant after 14 days without exposure to allergen
and SEB, and that terreic acid and dexamethasone
suppress the accumulation of these cells. Similar pat-
terns of leukocyte infiltration in terreic acid- and
dexamethasone-treated skin lesions (Fig. 2B) may
suggest that these agents target identical or overlap-
ping cell signaling pathways in the same cell types.
As bacterial infection is considered to be a precipi-
tating or exacerbating factor in human AD and terreic
acid has an antibiotic activity, we tested effects of am-
picillin application on skin lesions. Ampicillin also ex-
hibited some, albeit statistically insignificant
(p = 0.07), effects on improving clinical scores (Fig. 4
D).
DISCUSSION
In this study, we established a new protocol that can
induce AD-like skin lesions in dermatitis-prone NC
Nga mice with 100% efficiency. Half of the mice
showed clinical scores of 9 or higher. Induced skin le-
sions were basically identical to spontaneously devel-
oped skin lesions in NCNga mice, characterized by
infiltrations of immune cells (CD4+ T cells, eosino-
phils, mast cells, monocytesmacrophages, and neu-
trophils) and high serum IgE levels, mimicking clini-
cal findings in human AD patients. Consistent with
roles of infiltrated immune cells in the development
of skin lesions, terreic acid and dexamethasone were
both efficacious in treating induced skin lesions.
Therefore, this AD model seems useful to study
pathogenetic processes of AD and to evaluate the effi-
cacy of drug candidates.
Based on similarities discussed between induced
or spontaneously developed dermatitis in NCNga
mice and human AD, it would be fair to say that both
our NCNga model and other NCNga models mimic
limited attributes of human AD: for instance, food
sensitization is often found to be a trigger in human
patients, while it is not clear whether food allergen
plays any role in NCNga mice. Pruritis is a common
clinical manifestation in human AD. In our model,
however, the back skin was treated with Der fSEB
and occluded to prevent confounding effects of
scratching the skin area.
Terreic acid was originally isolated as an antibiotic
in 1942, but has not been used clinically probably be-
cause of its toxicity to the kidney. Our previous study
identified it as an inhibitor of Tec family kinases.26
Tec family kinases, such as Btk, Itk and Tec, act
downstream of Src and Syk family kinases, phospho-
rylate phospholipase C-γ, and regulate Ca2+ mobiliza-
tion.29 Our present results suggest that compounds,
like terreic acid, which have antibiotic as well as Tec
inhibitory activities, may be particularly useful in
treating AD skin lesions. Another advantage of target-
ing Tec family kinases therapeutically is that these
kinases are signal amplifiers in immune cell activa-
tion, but not an all-or-none switch like Syk.29,31 There-
fore, some immune cell functions will remain intact
with impaired activity of Tec family kinases. Thus, a
topical approach of skin treatment with terreic acid
and other Tec family inhibitors limits potential sys-
temic side effects. Although the mice treated with up
to 1% terreic acid stayed healthy and active with good
appetite, the long-term toxicity of TA to the kidney
and other organs remains to be carefully evaluated.
AD patients are known to be highly susceptible to
viral infections.32 For example, vaccination against
smallpox by scarification with vaccinia virus occasion-
ally causes serious complications termed eczema vac-
cinatum.33 Herpes simplex virus infection also causes
severe infection in AD patients termed eczema her-
peticum.32 Therefore, our AD model may also be use-
ful to study pathogenetic mechanisms of these viral
infections.
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